Also known as humanin · Wikipedia
Humanin is a 24-amino-acid mitochondrial-derived peptide first identified in 2001 by the Hashimoto laboratory in surviving neurons from an Alzheimer's-disease brain (Hashimoto et al., Proc Natl Acad Sci USA 2001). It is encoded by a short open reading frame within the mitochondrial 16S rRNA (MT-RNR2) gene and acts as a cytoprotective, anti-apoptotic signalling peptide with neuroprotective, metabolic, and IGF-axis-modulating properties in preclinical models (Lee, Cohen et al.). Circulating endogenous humanin declines with age. There are no completed human clinical trials of synthetic humanin or its analogs; all therapeutic claims remain preclinical. Vendors sell unmodified native sequence as a research chemical.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
Humanin is a 24-amino-acid peptide encoded within a short open reading frame in the mitochondrial 16S rRNA gene (MT-RNR2). It signals through a trimeric cell-surface receptor complex (CNTFR/WSX-1/gp130) and the formyl peptide receptor-like-1 (FPRL1/FPR2) to activate STAT3, JAK2, and ERK survival pathways (Hashimoto et al.
Pharmacokinetic properties
Half-life
Plasma half-life ~30 minutes (native humanin); analogs like S14G-humanin and HNG (HumaninG) are 1000x more potent and have extended activity
Routes
subcutaneous · intramuscular · intranasal · intravenous
Bioavailability
Not orally bioavailable. Endogenous circulating humanin declines with age. Synthetic analogs (HNG, S14G) used in most preclinical research outperform native peptide.
Amino-acid sequence
(21-aa mitochondria-derived peptide; full 21-aa sequence: MAPRGFSCLLLLTSEIDLPVI)
Use & research dosing
No human clinical dose has been established. Most published efficacy studies use the synthetic S14G-humanin (HNG) analog, reported to be ~1000-fold more potent than native humanin (Hashimoto et al., 2001) - this is not what most vendors sell. Preclinical rodent studies have used 1-10 mg/kg/day parenterally. Self-experimentation protocols commonly report 5-10 mg subcutaneously 2-3 times per week, sometimes paired with MOTS-c. These doses are not supported by controlled human PK or safety data.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Humanin was the first identified mitochondrial-derived peptide (Hashimoto et al., 2001) and anchors a peptide family that now includes MOTS-c and the SHLPs. Most of the strongest preclinical efficacy data come from the synthetic HNG (S14G-humanin) analog, which is roughly 1000-fold more potent than the native sequence - a crucial caveat because most vendor product is unmodified native humanin. There is no IND-stage human clinical program. All current human use is gray-market self-experimentation.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.